|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression
The National Institutes of Health experience
1 Transplantation and Autoimmunity Branch, National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland
2 Clinical Center Department of Transfusion Medicine, National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland
3 Special Procedures–Diagnostic Radiology Department, National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland
Address correspondence and reprint requests to David M. Harlan, MD, Chief, Transplantation and Autoimmunity Branch, NIDDK, National Institutes of Health/Department of Health and Human Services, Building 10, Room BN307, Bethesda, MD 20892. E-mail: davidmh{at}intra.niddk.nih.gov
OBJECTIVE—The aim of this study was to describe the National Institutes of Health’s experience initiating an islet isolation and transplantation center, including descriptions of our first six recipients, and lessons learned.
RESEARCH DESIGN AND METHODS—Six females with chronic type 1 diabetes, hypoglycemia unawareness, and no endogenous insulin secretion (undetectable serum C-peptide) were transplanted with allogenic islets procured from brain dead donors. To prevent islet rejection, patients received daclizumab, sirolimus, and tacrolimus.
RESULTS—All patients noted less frequent and less severe hypoglycemia, and one-half were insulin independent at 1 year. Serum C-peptide persists in all but one patient (follow-up 17–22 months), indicating continued islet function. Two major procedure-related complications occurred: partial portal vein thrombosis and intra-abdominal hemorrhage. While we observed no cytomegalovirus infection or malignancy, recipients frequently developed transient mouth ulcers, diarrhea, edema, hypercholesterolemia, weight loss, myelosuppression, and other symptoms. Three patients discontinued immunosuppressive therapy: two because of intolerable toxicity (deteriorating kidney function and sirolimus-induced pneumonitis) while having evidence for continued islet function (one was insulin independent) and one because of gradually disappearing islet function.
CONCLUSIONS—We established an islet isolation and transplantation program and achieved a 50% insulin-independence rate after at most two islet infusions. Our experience demonstrates that centers not previously engaged in islet transplantation can initiate a program, and our data and literature analysis support not only the promise of islet transplantation but also its remaining hurdles, which include the limited islet supply, procedure-associated complications, imperfect immunosuppressive regimens, suboptimal glycemia control, and loss of function over time.
Abbreviations: GCSF, granulocyte colony stimulating factor • IEQ, islet equivalent • NIH, National Institutes of Health
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Keymeulen, P. Gillard, C. Mathieu, B. Movahedi, G. Maleux, G. Delvaux, D. Ysebaert, B. Roep, E. Vandemeulebroucke, M. Marichal, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft PNAS, November 14, 2006; 103(46): 17444 - 17449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brissova, M. J. Fowler, W. E. Nicholson, A. Chu, B. Hirshberg, D. M. Harlan, and A. C. Powers Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal Microscopy J. Histochem. Cytochem., September 1, 2005; 53(9): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Warnock, R. M. Meloche, D. Thompson, R. J. Shapiro, M. Fung, Z. Ao, S. Ho, Z. He, L.-J. Dai, L. Young, et al. Improved Human Pancreatic Islet Isolation for a Prospective Cohort Study of Islet Transplantation vs Best Medical Therapy in Type 1 Diabetes Mellitus Arch Surg, August 1, 2005; 140(8): 735 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R.T. Lakey, and A.M. J. Shapiro Five-Year Follow-Up After Clinical Islet Transplantation Diabetes, July 1, 2005; 54(7): 2060 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Hering, R. Kandaswamy, J. D. Ansite, P. M. Eckman, M. Nakano, T. Sawada, I. Matsumoto, S.-H. Ihm, H.-J. Zhang, J. Parkey, et al. Single-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 Diabetes JAMA, February 16, 2005; 293(7): 830 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ryan, B. W. Paty, P. A. Senior, J. R.T. Lakey, D. Bigam, and A.M. J. Shapiro {beta}-Score: An assessment of {beta}-cell function after islet transplantation Diabetes Care, February 1, 2005; 28(2): 343 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff {beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes Diabetes, January 1, 2005; 54(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hirshberg, K. I. Rother, B. J. Digon III, and D. M. Harlan Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression: Response to Charles and Selam Diabetes Care, May 1, 2004; 27(5): 1250 - 1251. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Robertson Islet Transplantation as a Treatment for Diabetes -- A Work in Progress N. Engl. J. Med., February 12, 2004; 350(7): 694 - 705. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Harlan Gene-Altered Islets for Transplant: Giant Leap or Small Step? Endocrinology, February 1, 2004; 145(2): 463 - 466. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |